Integrated Network Pharmacology and Experimental Validation Approach to Systematically Elucidate the Cardioprotective Mechanisms of Shengmai Injection
Cardiovascular Therapeutics · 2026-01 · 2026 (1)
DOI: 10.1155/cdr/6915907 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Cardiovascular Therapeutics, online erschienen am 28.06.2026. Verfasst von Nan Hu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China. Hauptthemen laut MEDLINE: Drugs, Chinese Herbal, Cardiotonic Agents, Heart Failure, Myocardial Infarction. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Laboratory of Nano-Imaging and Drug-Loaded Preparation of Shanxi Province, Research and Innovation Team Project for Scientific Breakthroughs at Shanxi Bethune Hospital, Fundamental Research Program of Shanxi Province.
Abstract (Originalsprache)
Core to advancing the study of traditional Chinese medicine (TCM) mechanisms is the integrated “computational prediction–experimental verification” strategy, which enables the precise identification of therapeutic targets through multilevel technological integration. Within this framework, this study systematically investigates the therapeutic mechanisms of Shengmai injection (SMI) against heart failure following myocardial infarction (MI). Initially, using network pharmacology approaches, we systematically screened TCMSP, BATMAN, and disease databases to identify 237 common targets of SMI and chronic heart failure. Through Cytoscape‐based network topology analysis, we pinpointed 52 core targets, with KEGG pathway enrichment analysis revealing the PI3K‐AKT signaling pathway as the crucial pathway. Subsequently, molecular docking technology demonstrated strong binding affinity (calculated affinity: −6.171 kcal/mol) between vitamin E (an active constituent by network pharmacology analysis) and the core target AKT1. At the experimental validation level, we established a mouse MI model by ligating the left anterior descending coronary artery, with continuous administration of SMI for 4 weeks. Experimental results showed that SMI significantly improved cardiac function of chronic heart failure, reduced myocardial fibrosis, inhibited cardiomyocyte apoptosis, and promoted macrophage polarization toward the reparative M2 phenotype. In the H9c2 cell model, SMI effectively improves mitochondrial function of cardiac cells induced by H 2 O 2 and inhibits reactive oxygen species accumulation and mitochondrial membrane potential collapse. Mechanistic studies revealed that SMI regulates mitochondrial dysfunction by activating the AKT/Bcl‐2 signaling axis, upregulating Bcl‐2 expression, and inhibiting Bax. Through systematic methodological integration, this study not only elucidates the mechanism by which SMI inhibits mitochondrial dysfunction and macrophage polarization and attenuates ventricular remodeling through the AKT/Bcl‐2 pathway but also provides a referential multidisciplinary research paradigm for investigating the mechanisms of TCM formulations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.
- Institute of Medical Technology Research, Shanxi Medical University, Taiyuan, China, sxmu.edu.cn.
- The Radiology Department of Shanxi Provincial People's Hospital Affiliated to Shanxi Medical University, Taiyuan, China.
ORCID-Profile: Nan Hu, Hongnv Zhang, Zhenghao Wang, Shaodong Zhai, Ruiping Zhang
Förderung
- Key Laboratory of Nano-Imaging and Drug-Loaded Preparation of Shanxi Province
- Research and Innovation Team Project for Scientific Breakthroughs at Shanxi Bethune Hospital
- Fundamental Research Program of Shanxi Province
- Shanxi Provincial Administration of Traditional Chinese Medicine
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Hu, N., Zhang, H., Wang, Z., Zhai, S., & Zhang, R. (2026). Integrated Network Pharmacology and Experimental Validation Approach to Systematically Elucidate the Cardioprotective Mechanisms of Shengmai Injection. Cardiovascular Therapeutics, 2026(1). https://doi.org/10.1155/cdr/6915907
Vancouver
Hu N, Zhang H, Wang Z, Zhai S, Zhang R. Integrated Network Pharmacology and Experimental Validation Approach to Systematically Elucidate the Cardioprotective Mechanisms of Shengmai Injection. Cardiovascular Therapeutics. 2026;2026(1). doi:10.1155/cdr/6915907
BibTeX
@article{Hu2026,
author = {Hu, Nan and Zhang, Hongnv and Wang, Zhenghao and Zhai, Shaodong and Zhang, Ruiping},
title = {Integrated Network Pharmacology and Experimental Validation Approach to Systematically Elucidate the Cardioprotective Mechanisms of Shengmai Injection},
journal = {Cardiovascular Therapeutics},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/cdr/6915907}
}
EUVIMED